Exacerbation history is associated with medication and appointment adherence in MS

Journal of Behavioral Medicine

Volumn 34, Issue 5, 2011, Pages 330-338

  Hancock, Laura M ^a   Bruce, Jared M ^a   Lynch, Sharon G ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Disease modifying therapy; Electronic adherence monitoring; Exacerbation; Multiple sclerosis

Indexed keywords

ARTICLE; COHORT ANALYSIS; HOSPITAL MANAGEMENT; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY; STATISTICS;

APPOINTMENTS AND SCHEDULES; COHORT STUDIES; HUMANS; IMMUNOTHERAPY; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 80755136587     PISSN: 01607715     EISSN: 15733521     Source Type: Journal    
DOI: 10.1007/s10865-011-9316-x     Document Type: Review

References (55)

1. DW Anderson JH Ellenberg CM Leventhal SC Reingold M Rodriguez DH Silberberg 1992 Revised estimate of the prevalence of multiple sclerosis in the United States Annals of Neurology 31 333 336 10.1002/ana.410310317 1637140 10.1002/ana.410310317 1:STN:280:DyaK38zksVemsQ%3D%3D
2. PA Arnett FH Barwick JE Beeney 2008 Depression in multiple sclerosis: Review and theoretical proposal Journal of the International Neuropsychological Society 14 691 724 18764967
3. RHB Benedict E Wahlig R Bakshi I Fishman F Munschauer R Zivadinov, et al. 2005 Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change Journal of Neurological Sciences 231 29 34 10.1016/j.jns.2004.12.009 (Pubitemid 40432023)
4. JM Bruce P Arnett 2009 Clinical correlates of generalized worry in multiple sclerosis Journal of Clinical and Experimental Neuropsychology 31 698 705 19107677 10.1080/13803390802484789
5. JM Bruce AS Bruce PA Arnett 2007 Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS Journal of the International Neuropsychological Society 13 544 548 17445304 10.1017/S1355617707070658 (Pubitemid 47307495)
6. JM Bruce L Hancock P Arnett S Lynch 2010 Treatment adherence in multiple sclerosis: Association with emotional status, personality, and cognition Journal of Behavioral Medicine 33 219 227 20127401 10.1007/s10865-010-9247-y
7. JM Bruce L Hancock S Lynch 2010 Objective adherence monitoring in MS: Initial validation and association with self-report Multiple Sclerosis 16 112 120 19995835 10.1177/1352458509351897
8. JM Bruce D Polen PA Arnett 2007 Pain and affective memory biases interact to predict depressive symptoms in multiple sclerosis Multiple Sclerosis 13 58 66 17294612 10.1177/1352458506070229 1:STN:280:DC%2BD2s%2Fps1KgtA%3D%3D (Pubitemid 46152762)
9. M Clerico P Barbero G Contessa C Ferrero L Durelli 2007 Adherence to interferon-beta treatment and results of therapy switching Journal of the Neurological Sciences 259 104 108 17376486 10.1016/j.jns.2006.05.075 1:CAS:528:DC%2BD2sXnslWrs7g%3D (Pubitemid 47031209)
10. G Comi M Filippi F Barkhof L Durelli G Edan O Fernández, et al. 2001 Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study Lancet 357 1576 1582 11377645 10.1016/S0140- 6736(00)04725-5 1:CAS:528:DC%2BD3MXjslSit78%3D (Pubitemid 32488815)
11. PK Coyle 2008 Early treatment of multiple sclerosis to prevent neurologic damage Neurology 71 S3 S7 19064872 10.1212/WNL.0b013e31818f3d6f 1:CAS:528:DC%2BD1cXhsVOgsLnM
12. PK Coyle 2009 Disease-modifying agents in multiple sclerosis Annals of Indian Academy of Neurology 12 273 282 10.4103/0972-2327.58280 20182575 10.4103/0972-2327.58280 1:STN:280:DC%2BC3c7jvVegsQ%3D%3D
13. JA Cramer 1998 Consequences of intermittent treatment for hypertension: The case for medication compliance and persistence The American Journal of Managed Care 4 1563 1568 10338902 1:STN:280:DyaK1M7hvVGrtQ%3D%3D (Pubitemid 28555518)
14. BAC Cree O Khan D Bourdette DS Goodin JA Cohen RA Marrie, et al. 2004 Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis Neurology 63 2039 2045 15596747 1:STN:280: DC%2BD2cnitFKqtQ%3D%3D (Pubitemid 39636249)
15. MC Davis CM Tucker RS Fennell 1996 Family behavior, adaptation, and treatment adherence of pediatric nephrology patients Pediatric Nephrology 10 160 166 8703702 1:STN:280:DyaK283mslCltw%3D%3D (Pubitemid 26107472)
16. E Dietz GA Clum SE Chung L Leonard DA Murphy LV Perez, et al. 2010 Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities Journal of Adolescent Health 46 278 283 20159506 10.1016/j.jadohealth. 2009.06.013
17. A Duff GJ Latchford 2010 Motivational interviewing for adherence problems in cystic fibrosis Pediatric Pulmonology 45 211 220 20146366
18. J Finney KL Lemanek CJ Brophy MF Cataldo 1990 Pediatric appointment keeping: Improving adherence in a primary care allergy clinic Journal of Pediatric Psychology 15 571 579 2258800 10.1093/jpepsy/15.4.571 1:STN:280:DyaK3M%2FnvF2ksA%3D%3D (Pubitemid 20366301)
19. C Fraser O Hadjimichael T Vollmer 2003 Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis Journal of Neuroscience Nursing 35 163 174 12830664 10.1097/01376517-200306000-00006
20. DS Goodin 2008 Disease-modifying therapy in multiple sclerosis: Update and clinical implications Neurology 71 8 13 10.1212/WNL.0b013e31818f3d8b
21. DS Goodin EM Frohman GP Garmany Jr J Halper WH Likosky FD Lublin, et al. 2002 Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for clinical practice guidelines Neurology 58 169 178 11805241 1:STN:280:DC%2BD38%2FnvV2htw%3D%3D (Pubitemid 34086933)
22. J Hobart J Freeman A Thompson 2000 Kurtzke scales revisited: The application of psychometric methods to clinical intuition Brain 123 1027 1040 10775547 10.1093/brain/123.5.1027 (Pubitemid 30224198)
23. A Interian I Martinez LI Rios J Krejci PJ Guarnaccia 2010 Adaptation of a motivational interviewing intervention to improve antidepressant adherence among Latinos Cultural Diversity and Ethnic Minority Psychology 16 215 225 10.1037/a0016072 20438160 10.1037/a0016072
24. LD Jacobs RW Beck JH Simon RP Kinkel CM Brownscheidle TJ Murray, et al. 2001 Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis American Journal of Opthamology 131 898 904
25. LD Jacobs DL Cookfair RA Rudick RM Herndon JR Richert AM Salazar, et al. 1996 Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Annals of Neurology 39 285 294 8602746 10.1002/ana.410390304 1:CAS:528:DyaK28XisFyrsLY%3D (Pubitemid 26100751)
26. KP Johnson BR Brooks JA Cohen CC Ford J Goldstein RP Lisak, et al. 1995 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1268 1276 7617181 1:STN:280:DyaK2Mzkt1eqtQ%3D%3D
27. L Kappos CH Polman MS Freedman G Edan HP Hartung DH Miller, et al. 2006 Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 1242 1249 16914693 10.1212/01.wnl.0000237641.33768.8d 1:CAS:528:DC%2BD28XhtFyqtLfL (Pubitemid 44563835)
28. AJ Karter MM Parker HH Moffet A Ahmed A Ferrara JY Liu, et al. 2004 Missed appointments and poor glycemic control: An opportunity to identify high-risk diabetic patients Medical Care 42 110 115 14734947 10.1097/01.mlr.0000109023.64650.73
29. BC Kieseier H Wiendl VI Leussink O Stuve 2008 Immunomodulatory treatment strategies in multiple sclerosis Journal of Neurology 255 15 21 19300955 10.1007/s00415-008-6004-z 1:CAS:528:DC%2BD1MXht1WhurjP
30. JF Kurtzke 1983 Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS) Neurology 33 1444 1452 6685237 1:STN:280:DyaL2c%2FktValsQ%3D%3D (Pubitemid 14237132)
31. FD Lublin SC Reingold 1996 Defining the clinical course of multiple sclerosis: Results of an international survey Neurology 46 907 911 8780061 1:STN:280:DyaK28zntlOksg%3D%3D (Pubitemid 26134623)
32. S Maxwell R Maljanian S Horowitz MA Pianka Y Cabrera J Greene 2001 Effectiveness of reminder systems on appointment adherence rates Journal of Health Care for the Poor and Underserved 12 504 514 11688199 1:STN:280:DC%2BD3Mnjs1Snsw%3D%3D (Pubitemid 33595192)
33. JB McClure SL Catz PJ Brantley 1999 Early appointment adherence among persons living with HIV AIDS and Behavior 3 157 165 10.1023/A:1025492108281 (Pubitemid 29316242)
34. Medley, A. R., & Powell, T. (2010). Motivational interviewing to promote self-awareness and engagement in rehabilitation following acquired brain injury: A conceptual review. Neuropsychological Rehabilitation, Epub ahead of print.
35. CI Mitsonis IM Zervas PA Mitropoulos NP Dimopoulos CR Soldatos CM Potagas 2008 The impact of stressful life events on risk of relapse in women with multiple sclerosis: A prospective study European Psychiatry 23 497 504 10.1016/j.eurpsy.2008.06.003 18778921 10.1016/j.eurpsy.2008.06.003
36. DC Mohr AC Boudewyn W Likosky E Levine DE Goodkin 2001 Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject Annals of Behavioral Medicine 23 125 132 11394554 10.1207/S15324796ABM2302-7 1:STN:280:DC%2BD3Mzislemsg%3D%3D (Pubitemid 32488430)
37. DC Mohr DE Goodkin W Likosky N Gatto KA Baumann RA Rudick 1997 Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis Archives of Neurology 54 531 533 9152109 1:STN:280: DyaK2s3ps1Knsg%3D%3D (Pubitemid 27204238)
38. B Mollon AM Holbrook K Keshavjee S Troyan K Gaebel L Thabane 2008 Automated telephone reminder messages can assist electronic diabetes care Journal of Telemedicine and Telecare 14 32 36 10.1258/jtt.2007.070702 18318927 10.1258/jtt.2007.070702
39. CG Moore P Wilson-Witherspoon JC Probst 2001 Time and money: Effects of no-shows at a family practice residency clinic Family Medicine 33 522 527 11456244 1:STN:280:DC%2BD38%2FitF2msg%3D%3D (Pubitemid 32607186)
40. Outlaw, A., Naar-King, S., Green-Jones, M., Wright, K., Condon, K., Sherry, L., & Janisse, H. (2010). Brief report: Predictors of optimal HIV appointment adherence in minority youth: A prospective study. Journal of Pediatric Psychology, 35, 1011-1015. doi: 10.1093/jpepsy/jsq002.
41. F Patti 2009 Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence Patient Preference and Adherence 4 1 9
42. V Pesata G Palliga AA Webb 1999 A descriptive study of missed appointments: Families' perceptions of barriers to care Journal of Pediatric Health Care 13 178 182 10690082 10.1016/S0891-5245(99)90037-8 1:STN:280:DC%2BD3c7lsVKksA%3D%3D
43. CH Polman SC Reingold G Edan M Filippi HP Hartung L Kappos, et al. 2005 Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Annals of Neurology 58 840 846 16283615 10.1002/ana.20703 (Pubitemid 41746873)
44. Pryse-Phillips, W., & Costello, F. (2001). The epidemiology of multiple sclerosis. New York: Marcel Dekker, Inc.
45. J Rio J Porcel N Tellez A Sanchez-Betancourt M Tintore MJ Arevalo, et al. 2005 Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis Multiple Sclerosis 11 306 309 10.1191/1352458505ms1173oa 15957512 10.1191/1352458505ms1173oa 1:CAS:528:DC%2BD2MXlslKntLc%3D (Pubitemid 40775187)
46. B Satiani S Miller D Patel 2009 No-show rates in the vascular laboratory: Analysis and possible solutions Journal of Vascular and International Radiology 20 87 91 10.1016/j.jvir.2008.09.027 10.1016/j.jvir.2008.09.027
47. GA Schumacher G Beebe RF Kibler LT Kurland JF Kurtzke F McDowell, et al. 1965 Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis Annals of the New York Academy of Sciences 122 552 568 10.1111/j.1749-6632.1965.tb20235.x
48. SC Steinberg RJ Faris CF Chang A Chan MA Tankersley 2010 Impact of adherence to inteferons in the treatment of multiple sclerosis: A non-experimental, retrospective, cohort study Clinical Drug Investigation 30 89 100 20067327 10.2165/11533330-000000000-00000 1:CAS:528:DC%2BC3cXislSrtrc%3D
49. The IFNB Multiple Sclerosis Study Group 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 655 661
50. AG Uribe KT Ho B Agee G McGwin BJ Fessler HM Bastian 2004 Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: Data from the LUMINA cohort Lupus 13 561 568 10.1191/ 0961203304lu1061oa 15462484 10.1191/0961203304lu1061oa 1:STN:280: DC%2BD2cvpsVemsQ%3D%3D (Pubitemid 39145484)
51. EA Walker M Molitch MK Kramer S Kahn Y Ma S Edelstein, et al. 2006 Adherence to preventive medications: Predictors and outcomes in the Diabetes Prevention Program Diabetes Care 29 1997 2002 16936143 10.2337/dc06-0454 (Pubitemid 44871177)
52. MT Wallin WF Page JF Kurtzke 2004 Multiple sclerosis in US veterans of the Vietnam era and later military service: Race, sex, and geography Annals of Neurology 55 65 71 14705113 10.1002/ana.10788 (Pubitemid 38067362)
53. EU Walther R Hohlfeld 1999 Multiple sclerosis: Side effects of interferon beta therapy and their management Neurology 53 1622 1627 10563602 1:CAS:528:DyaK1MXnvVKnsro%3D (Pubitemid 29530329)
54. World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. Retrieved from http://www.who.int/chp/knowledge/ publications/adherence-report/en/.
55. R Zivadinov M Zorzon MA Tommasi D Nasuelli M Bernardi L Monti-Bragadin, et al. 2003 A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a Journal of the Neurological Sciences 216 113 118 14607312 10.1016/S0022-510X(03)00225-9 1:CAS:528:DC%2BD3sXos1Klsrk%3D (Pubitemid 37371875)